CBD Shows Antitumor Effects Against Bone Cancer by Targeting an Inflammatory Pathway
CBD suppressed osteosarcoma cell growth and tumor formation in mice by directly binding to NF-kB and disrupting the TNF-alpha/NF-kB/CCL5 inflammatory signaling axis.
Quick Facts
What This Study Found
CBD directly binds the NF-kB subunit p65, disrupting a positive feedback loop between NF-kB and CCL5 that drives osteosarcoma inflammation and proliferation. This was validated in both cell culture and mouse tumor models.
Key Numbers
CBD suppressed proliferation (EdU assay), migration, and invasion in cell culture. Inhibited xenograft tumor growth in vivo. Molecular binding to p65 confirmed by four complementary methods.
How They Did This
Comprehensive preclinical study using cell viability assays, functional assays (proliferation, migration, invasion), mouse xenograft tumors, network pharmacology, RNA-seq, and molecular binding confirmation (CETSA, SPR, ITC, molecular docking).
Why This Research Matters
Osteosarcoma is an aggressive bone cancer with limited treatment options. Identifying that CBD targets a specific inflammatory pathway provides a mechanistic rationale for further investigation, beyond general anti-cancer claims.
The Bigger Picture
Anti-cancer claims for CBD are common but often lack mechanistic evidence. This study provides the first detailed molecular mechanism for CBD's effects on osteosarcoma, moving beyond 'CBD kills cancer cells' to identifying exactly how and where it acts.
What This Study Doesn't Tell Us
Preclinical only — mouse xenograft models don't fully replicate human bone cancer. CBD concentrations used may not be achievable in human patients. Single cancer type studied.
Questions This Raises
- ?Could CBD enhance existing osteosarcoma treatments as a combination therapy?
- ?Would the NF-kB-targeting mechanism apply to other cancers driven by this inflammatory pathway?
Trust & Context
- Key Stat:
- Evidence Grade:
- Thorough preclinical investigation with multiple validation methods, but remains far from clinical application.
- Study Age:
- Recent study providing the first evidence of CBD targeting the TNF-alpha/NF-kB/CCL5 axis in osteosarcoma.
- Original Title:
- Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.
- Published In:
- Phytomedicine : international journal of phytotherapy and phytopharmacology, 145, 157066 (2025)
- Authors:
- Yang, Fan(3), Duan, Shuqin(2), Liu, Jingwei, An, Zhechao, Liu, Wangyang, Wang, Xinyue, Zhang, Tingting, Liu, Mingyu, Li, Fengda, Wu, Wei, Liu, Yingzhe, Tang, Jianyong, Wang, Xiaojuan, Xu, Wenhui, Qi, Wenyi, Liu, Yunhe, Li, Liangliang, Li, Yuan, Liu, Xin, Yang, Baofeng, Zhang, Zheng, Wang, Li, Yang, Lei
- Database ID:
- RTHC-07992
Evidence Hierarchy
Frequently Asked Questions
Can CBD treat bone cancer?
This preclinical study shows CBD can inhibit osteosarcoma cells and tumors in mice by targeting a specific inflammatory pathway. However, human clinical trials would be needed before making any treatment claims.
How does CBD target cancer cells?
In this study, CBD directly binds to a protein called p65 (part of NF-kB), disrupting an inflammatory signaling loop that cancer cells use to grow and spread.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07992APA
Yang, Fan; Duan, Shuqin; Liu, Jingwei; An, Zhechao; Liu, Wangyang; Wang, Xinyue; Zhang, Tingting; Liu, Mingyu; Li, Fengda; Wu, Wei; Liu, Yingzhe; Tang, Jianyong; Wang, Xiaojuan; Xu, Wenhui; Qi, Wenyi; Liu, Yunhe; Li, Liangliang; Li, Yuan; Liu, Xin; Yang, Baofeng; Zhang, Zheng; Wang, Li; Yang, Lei. (2025). Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 145, 157066. https://doi.org/10.1016/j.phymed.2025.157066
MLA
Yang, Fan, et al. "Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.." Phytomedicine : international journal of phytotherapy and phytopharmacology, 2025. https://doi.org/10.1016/j.phymed.2025.157066
RethinkTHC
RethinkTHC Research Database. "Antitumor effects of cannabidiol (CBD) on osteosarcoma by ta..." RTHC-07992. Retrieved from https://rethinkthc.com/research/yang-2025-antitumor-effects-of-cannabidiol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.